GlassScriptPhysician profile
Morris Papernik
NPI 1457326787
$15,181.58
in general payments reported to CMS, 2019-2025
63 companies · $4,568 in 2025
The $4,568 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,627 · 2020: $800 · 2021: $20.14 · 2022: $1,446 · 2023: $3,406 · 2024: $3,314 · 2025: $4,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,963.19 |
| Education | $325.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,850.51 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $1,353.52 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,024.03 | 2019-2025 | Rexulti |
| Glaxosmithkline, LLC. | $888.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $876.73 | 2019-2020 | |
| Pfizer INC. | $868.34 | 2019-2025 | |
| Novo Nordisk INC | $791.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $621.19 | 2019-2025 | Veozah |
| Axsome Therapeutics, INC. | $498.08 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Jazz Pharmaceuticals INC. | $476.31 | 2023-2025 | |
| Amgen INC. | $439.71 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $424.25 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.22 | 2019-2025 | Xifaxan, Relistor |
| Harmony Biosciences LLC | $406.60 | 2023-2025 | Wakix |
| Ardelyx, INC. | $379.38 | 2024-2025 | Ibsrela |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Papernik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.